⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10524099 | 0.96 | — | — | |
| SCHEMBL2491334 | 0.84 | — | — | |
| SCHEMBL14698534 | 0.67 | — | — | |
| SCHEMBL2809033 | 0.67 | — | — | |
| SCHEMBL11232891 | 0.65 | — | — | |
| SCHEMBL145953 | 0.61 | — | — | |
| SCHEMBL1457573 | 0.61 | — | — | |
| SCHEMBL5899117 | 0.61 | — | — | |
| SCHEMBL14331814 | 0.61 | — | — | |
| SCHEMBL18843427 | 0.61 | KDM4E (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710118-B2 | Nano-pigment inkjet ink composition that has a low odor and is environmentally-friendly | JETBEST CORPORATION (TW) | 2014-04-29 | — | — | US | claimed |
| CN-1181056-C | 4 -acylamino piperidin-N-oxides | �����ɷ� | 2004-12-22 | — | — | CN | claimed |
| EP-4653049-A2 | CGRP ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2025-11-26 | — | — | EP | disclosed |
| EP-3983417-B1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-20250136616-A1 | CGRP ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2025-05-01 | — | — | US | disclosed |
| US-12227521-B2 | CGRP antagonist compounds | NXERA PHARMA UK LIMITED (GB) | 2025-02-18 | — | — | US | disclosed |
| CN-114245797-B | CGRP antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-09-17 | — | — | CN | disclosed |
| CN-116710430-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220288201-A1 | COMBINATION THERAPY FOR TREATING RAS-MUTANT CANCERS | H LEE MOFFITT CANCER AND RES INSTITUTE INC (US) | 2022-09-15 | — | — | US | disclosed |
| US-20220251110-A1 | CGRP ANTAGONIST COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2022-08-11 | — | — | US | disclosed |
| EP-3983417-A1 | CGRP ANTAGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-04-20 | — | — | EP | disclosed |
| WO-2012072548-A2 | CROSSLINKED POLYAMIDES | BASF SE (DE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120088899-A1 | PROCESS FOR PRODUCING MONOMER COMPOSITIONS AND USE OF THESE FOR PRODUCING A POLYAMIDE MOLDING | BASF SE (DE) | 2012-04-12 | — | — | US | disclosed |
| WO-2012045806-A1 | METHOD FOR PRODUCING MONOMER COMPOSITIONS, AND USE THEREOF FOR PRODUCING A MOLDED POLYAMIDE PART | BASF SE (DE) | 2012-04-12 | — | — | WO | disclosed |
| EP-2391603-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2011-12-07 | — | — | EP | disclosed |
| US-20110288258-A1 | CROSSLINKED POLYAMIDE | BASF SE (DE) | 2011-11-24 | — | — | US | disclosed |
| CN-102238950-A | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use | CHDI INC (US) | 2011-11-09 | — | — | CN | disclosed |
| US-20100197715-A1 | PIPERIDINE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010086251-A1 | AROYLAMINO - AND HETEROAROYLAMINO-SUBSTITUTED PIPERIDINES AS GLYT-1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-05 | — | — | WO | disclosed |
| CN-1138505-C | Anti-angiogenic compositions and methods of use | — | 2004-02-18 | — | — | CN | disclosed |